Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 1:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 13,157 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pulmonary/Respiratory Diseases Clear all
Completed Not applicable Interventional Results available

Using Intravenous Heparin Versus Standard of Care Subcutaneous Heparin to Prevent Clots After Surgery

NCT01608906
View directory record Official record
Conditions
Venous Thrombosis
Interventions
low dose intravenous heparin (LDIVH), Heparin
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Sep 26, 2026, 1:03 PM EDT
Completed Phase 1 Interventional

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Stage I-IIIB Non-Small Cell Lung Cancer After Completion of Radiation Therapy Alone or Combined Radiation Therapy and Chemotherapy

NCT00738452
View directory record Official record
Conditions
Lung Cancer
Interventions
high performance liquid chromatography, pharmacological study, radionuclide imaging, single photon emission computed tomography, radiation therapy, yttrium Y 90 anti-CEA monoclonal antibody cT84.66
Other · Procedure · Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2018 · Synced Sep 26, 2026, 1:03 PM EDT
Completed Not applicable Interventional Results available

RECOVER-NEURO: Platform Protocol to Measure the Effects of Cognitive Dysfunction Interventions on Long COVID Symptoms

NCT05965752
View directory record Official record
Conditions
Long COVID, Long COVID-19, Long COVID19
Interventions
BrainHQ/Active Comparator Activity, BrainHQ, PASC CoRE, tDCS-active, tDCS-sham
Other · Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
24
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Sep 26, 2026, 1:03 PM EDT
Terminated Phase 2 Interventional

Topotecan in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer

NCT00087048
View directory record Official record
Conditions
Lung Cancer
Interventions
topotecan hydrochloride
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
2
States / cities
Detroit, Michigan • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 21, 2016 · Synced Sep 26, 2026, 1:03 PM EDT
Recruiting No phase listed Observational

Evaluation Of The Lung Microbiome In NTM Bronchiectasis

NCT02779478
View directory record Official record
Conditions
Nontuberculous Mycobacteria, Bronchiectasis
Interventions
Bronchoscopy
Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2031
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 26, 2026, 1:03 PM EDT
Completed Phase 1 Interventional Results available

Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma

NCT03229278
View directory record Official record
Conditions
Lymphoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Cancer, Recurrent Bladder Carcinoma, Recurrent Classical Hodgkin Lymphoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Renal Cell Carcinoma, Stage III Bladder Cancer, Stage III Lymphoma, Stage III Non-Small Cell Lung Cancer AJCC v7, Stage III Renal Cell Cancer, Stage III Skin Melanoma, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Skin Melanoma, Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Bladder Cancer, Stage IV Lymphoma, Stage IV Non-Small Cell Lung Cancer AJCC v7, Stage IV Renal Cell Cancer, Stage IV Skin Melanoma, Stage IVA Bladder Cancer, Stage IVB Bladder Cancer, Unresectable Head and Neck Squamous Cell Carcinoma, Unresectable Solid Neoplasm
Interventions
Enzyme Inhibitor Therapy, Laboratory Biomarker Analysis, Nivolumab, Pembrolizumab
Drug · Other · Biological
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Sep 26, 2026, 1:03 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Identification of Genes Associated With Lung Disease in Patients With Rheumatoid Arthritis

NCT00001885
View directory record Official record
Conditions
Healthy, Pulmonary Fibrosis, Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
21 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 26, 2026, 1:03 PM EDT
Withdrawn No phase listed Observational

Cardiovascular Manifestations of COVID-19

NCT04701515
View directory record Official record
Conditions
COVID-19
Interventions
Chart review
Other
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Timeline
2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 26, 2026, 1:03 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional Results available

Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy

NCT04655976
View directory record Official record
Conditions
Lung Cancer, Non-Small Cell
Interventions
Cobolimab, Dostarlimab, Docetaxel
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
758 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
17
States / cities
Fountain Valley, California • Walnut Creek, California • Norwich, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 26, 2026, 1:03 PM EDT
Completed Phase 4 Interventional Results available

Effects of a Orally Inhaled Fluticasone Furoate on Growth Velocity in Prepubertal, Paediatric Subjects With Asthma Over a Year

NCT02889809
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone furoate, Placebo, Montelukast, Short Acting Beta 2 Agonist
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
5 Years to 9 Years
Enrollment
477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
18
States / cities
Little Rock, Arkansas • Huntington Beach, California • Homestead, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Sep 26, 2026, 1:03 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Effects of Montelukast on Occult Exercise-Induced Bronchospasm in Athletes

NCT00375232
View directory record Official record
Conditions
Exercise-Induced Bronchospasm
Interventions
Administration of montelukast or placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 50 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 6, 2016 · Synced Sep 26, 2026, 1:03 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Alendronate to Prevent Loss of Bronchoprotection in Asthma

NCT02230332
View directory record Official record
Conditions
Asthma
Interventions
Alendronate, Placebo
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
10
States / cities
Tucson, Arizona • San Francisco, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Sep 26, 2026, 1:03 PM EDT
Terminated Not applicable Interventional

Ketogenic Diet With Chemoradiation for Lung Cancer (KETOLUNG)

NCT01419587
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Ketogenic diet
Dietary Supplement
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jan 7, 2018 · Synced Sep 26, 2026, 1:03 PM EDT
Active, not recruiting Phase 2 Interventional

Treatment of ARDS With Instilled T3

NCT04115514
View directory record Official record
Conditions
ARDS, Human, Lung, Wet, Thyroid, Pulmonary Edema, Lung Inflammation
Interventions
Liothyronine Sodium (T3+0.9% sodium chloride) modified formulation specifically for airway instillation., Non-intervention
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Edina, Minnesota • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 26, 2026, 1:03 PM EDT
Completed Phase 3 Interventional Results available

New Breath Actuated MDI Symbicort Compared to Symbicort pMDI and Budesonide pMDI for 12 Weeks Twice a Day

NCT01360021
View directory record Official record
Conditions
Asthma
Interventions
Symbicort, Budesonide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
31
States / cities
Huntington Beach, California • Long Beach, California • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2014 · Synced Sep 26, 2026, 1:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Empowering Hispanic Patients' Lung Cancer Screening Uptake (Empower Latinx)

NCT06225414
View directory record Official record
Conditions
Lung Cancer
Interventions
Usual Care, Brief Patient Education, Patient education, Referral to financial navigation resources, Patient Reminders, Provider Reminders
Other · Behavioral
Lead sponsor
University of California, Irvine
Other
Eligibility
50 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
10
States / cities
Anaheim, California • Costa Mesa, California • Irvine, California + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Sep 26, 2026, 1:03 PM EDT
Recruiting Not applicable Interventional

Gastrointestinal Response of Pediatric Cystic Fibrosis Patients on Mediterranean Diet

NCT07223255
View directory record Official record
Conditions
Cystic Fibrosis (CF), Cystic Fibrosis Gastrointestinal Disease
Interventions
Mediterranean diet
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
3 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Lebanon, New Hampshire • Manchester, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 26, 2026, 1:03 PM EDT
Active, not recruiting Not applicable Interventional Results available

Home-based Brain Stimulation Treatment for Post-acute Sequelae of COVID-19 (PASC)

NCT05092516
View directory record Official record
Conditions
Dysexecutive Syndrome, Post-Acute Sequelae of COVID-19
Interventions
Active tDCS, Sham tDCS
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 26, 2026, 1:03 PM EDT
Enrolling by invitation Not applicable Interventional

Virtual Nurse and Social Worker Palliative Care Team to Improve Quality of Life in Veterans With Heart Failure or COPD

NCT07714252
View directory record Official record
Conditions
Heart Failure, Pulmonary Disease, Chronic Obstructive, Interstitial Lung Disease
Interventions
Virtual Nurse and Social Worker Palliative Care Team, Enhanced Implementation Support, Standard Implementation Support
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
7
States / cities
Phoenix, Arizona • Long Beach, California • Aurora, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 26, 2026, 1:03 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Vaccine Observation to Include All Communities for Equitable Science

NCT04770649
View directory record Official record
Conditions
Vaccine Response Impaired, Vaccine Adverse Reaction
Interventions
COVID-19 vaccine
Biological
Lead sponsor
Persephone Biosciences
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Sep 26, 2026, 1:03 PM EDT
Completed Phase 2 Interventional

Bevacizumab and Carboplatin/Paclitaxel and Radiation in Non-Small Cell Lung Cancer

NCT00578149
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Bevacizumab, Carboplatin, Paclitaxel
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 20, 2007 · Synced Sep 26, 2026, 1:03 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Tolerability of Inhaled Nitric Oxide in Patients With Cystic Fibrosis

NCT00570349
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Nitric Oxide for Inhalation, Nitrogen
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
12 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Sep 26, 2026, 1:03 PM EDT
Completed Phase 2 Interventional Results available

Aztreonam Lysine for Pseudomonas Infection Eradication Study

NCT01375049
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Aztreonam for Inhalation Solution (AZLI)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
3 Months to 17 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
23
States / cities
Phoenix, Arizona • Jacksonville, Florida • Orlando, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2014 · Synced Sep 26, 2026, 1:03 PM EDT
Completed No phase listed Observational

Estimating Prevalence of COVID-19 Infection and SARS-CoV-2 Antibodies in MS Patients

NCT04682548
View directory record Official record
Conditions
Multiple Sclerosis, Covid19
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 60 Years
Enrollment
920 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Sep 26, 2026, 1:03 PM EDT